Welcome to LookChem.com Sign In|Join Free
  • or
Hybio Pharmaceutica Co.,LtdFor Weight Losing and Diabetics Liraglutide CAS No. 204656-20-2//www.lookchem.com/300w/

You May Like:

Communicate with Supplier:

Ms. ye
Ms. ye: What can I do for you?

For Weight Losing and Diabetics Liraglutide CAS No. 204656-20-2 CAS NO.204656-20-2

Min.Order Quantity:
1 Gram
Payment Terms:

Add to Inquiry Cart

Product Details


  • Liraglutide, Liraglutido
  • лираглутид
  • Liraglutida

Quick Details

  • ProName: For Weight Losing and Diabetics Liragl...
  • CasNo: 204656-20-2
  • Molecular Formula: C172h265n43o51
  • Appearance: white
  • Application: Medical uses Liraglutide is a once-da...
  • DeliveryTime: Ready in Stock
  • PackAge: Aluminum Foil Bag
  • Port: HK/Shenzhen
  • ProductionCapacity: 500 Kilogram/Year
  • Purity: ≥98%
  • Storage: 2-8 degree
  • Transportation: Cold chain and cool storage delivery f...
  • LimitNum: 1 Gram


The first listed company in peptides industry, mature process, stable and advaced technology,API capacity reachease to 500kg with 3 main factory sites.


Liraglutide Specification:

CAS No.: 204656-20-2
Molecular Formula:C172H265N43O51
Molar Mass:3751.202g/mol
Sequence: H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(N-ε-(Nα-Palmitoyl-L-γ-glutamyl))-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH.

Type 2 diabetes
Liraglutide improves control of blood glucose. It reduces meal-related hyperglycemia (for 24 hours after administration) by increasing insulin secretion (only) when required by increasing glucose levels, delaying gastric emptying, and suppressing prandial glucagon secretion.

It acts in a glucose-dependent manner, meaning it will stimulate insulin secretion only when blood glucose levels are higher than normal, preventing "overshoot". Consequently, it shows negligible risk of hypoglycemia.
It has the potential for inhibiting apoptosis and stimulating regeneration of beta cells (seen in animal studies).
It decreases appetite and inhibits body weight gain, as shown in a head-to-head study versus glimepiride.
It lowers blood triglyceride levels.

Liraglutide has been approved as an injectable adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients. The specified criteria are an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight), in the presence of at least one weight-related comorbid condition (e.g. hypertension, type 2 diabetes mellitus, or dyslipidemia). In late 2014, data were reported from the SCALE™ Obesity and Prediabetes trial, which is a randomised, double-blind, placebo-controlled, multinational trial in non-diabetic people with obesity and non-diabetic people who are overweight with comorbidities.

Send a message direct to supplier(s)

Enter email or Member ID
Hybio Pharmaceutica Co.,Ltd

-Enter between 20 to 2000 letters.English only. Word count:0 letter(s).
-We suggest you include in your inquiry a brief introduction to your company as well as your product requirements